Summary
The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Essential resource for top-line data and analysis covering the BRIC generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.
- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $87.2 billion in 2016. China was the fastest growing country with a CAGR of 15.5% over the 2012-16 period.
- Within the generics industry, China is the leading country among the BRIC nations with market revenues of $63.1 billion in 2016. This was followed by India, Russia and Brazil with a value of $13.3, $7.0, and $3.9 billion, respectively.
- China is expected to lead the generics industry in the BRIC nations with a value of $104.9 billion in 2021, followed by India, Russia, Brazil with expected values of $25.8, $9.6 and $4.1 billion, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the BRIC generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
- Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
- Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
Reasons to buy
- What was the size of the BRIC generics market by value in 2016?
- What will be the size of the BRIC generics market in 2021?
- What factors are affecting the strength of competition in the BRIC generics market?
- How has the market performed over the last five years?
- Who are the top competitors in the BRIC generics market?
'
Table of Contents
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
BRIC Generics
Industry Outlook
Generics in Brazil
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine
List of Tables
Table 1: BRIC generics industry, revenue($bn), 2012-21
Table 2: BRIC generics industry, revenue($bn), 2012-16
Table 3: BRIC generics industry, revenue($bn), 2016-21
Table 4: Brazil generics market value: $ billion, 2012–16
Table 5: Brazil generics market volume: % of total pharma volume, 2012–16
Table 6: Brazil generics market geography segmentation: $ billion, 2016
Table 7: Brazil generics market value forecast: $ billion, 2016–21
Table 8: Brazil generics market volume forecast: % of total pharma volume, 2016–21
Table 9: Brazil size of population (million), 2012–16
Table 10: Brazil gdp (constant 2005 prices, $ billion), 2012–16
Table 11: Brazil gdp (current prices, $ billion), 2012–16
Table 12: Brazil inflation, 2012–16
Table 13: Brazil consumer price index (absolute), 2012–16
Table 14: Brazil exchange rate, 2012–16
Table 15: China generics market value: $ billion, 2012–16
Table 16: China generics market volume: % of total pharma volume, 2012–16
Table 17: China generics market geography segmentation: $ billion, 2016
Table 18: China generics market value forecast: $ billion, 2016–21
Table 19: China generics market volume forecast: % of total pharma volume, 2016–21
Table 20: China size of population (million), 2012–16
Table 21: China gdp (constant 2005 prices, $ billion), 2012–16
Table 22: China gdp (current prices, $ billion), 2012–16
Table 23: China inflation, 2012–16
Table 24: China consumer price index (absolute), 2012–16
Table 25: China exchange rate, 2012–16
Table 26: India generics market value: $ billion, 2012–16
Table 27: India generics market volume: % of total pharma volume, 2012–16
Table 28: India generics market geography segmentation: $ billion, 2016
Table 29: India generics market value forecast: $ billion, 2016–21
Table 30: India generics market volume forecast: % of total pharma volume, 2016–21
Table 31: India size of population (million), 2012–16
Table 32: India gdp (constant 2005 prices, $ billion), 2012–16
Table 33: India gdp (current prices, $ billion), 2012–16
Table 34: India inflation, 2012–16
Table 35: India consumer price index (absolute), 2012–16
Table 36: India exchange rate, 2012–16
Table 37: Russia generics market value: $ billion, 2012–16
Table 38: Russia generics market volume: % of total pharma volume, 2012–16
Table 39: Russia generics market geography segmentation: $ billion, 2016
Table 40: Russia generics market value forecast: $ billion, 2016–21
Table 41: Russia generics market volume forecast: % of total pharma volume, 2016–21
Table 42: Russia size of population (million), 2012–16
Table 43: Russia gdp (constant 2005 prices, $ billion), 2012–16
Table 44: Russia gdp (current prices, $ billion), 2012–16
Table 45: Russia inflation, 2012–16
Table 46: Russia consumer price index (absolute), 2012–16
Table 47: Russia exchange rate, 2012–16
Table 48: O Ache Laboratorios Farmaceuticos S.A.: key facts
Table 49: EMS Sigma Pharma: key facts
Table 50: Eurofarma Laboratórios S.A.: key facts
Table 51: Sanofi SA: key facts
Table 52: Sanofi SA: key financials ($)
Table 53: Sanofi SA: key financials (€)
Table 54: Sanofi SA: key financial ratios
Table 55: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 56: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 57: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 58: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 59: Mylan Inc.: key facts
Table 60: Mylan Inc.: key financials ($)
Table 61: Mylan Inc.: key financial ratios
Table 62: Sandoz International GmbH: key facts
Table 63: Aurobindo Pharma Limited: key facts
Table 64: Aurobindo Pharma Limited: key financials ($)
Table 65: Aurobindo Pharma Limited: key financials (Rs.)
Table 66: Aurobindo Pharma Limited: key financial ratios
Table 67: Cipla Limited: key facts
Table 68: Cipla Limited: key financials ($)
Table 69: Cipla Limited: key financials (Rs.)
Table 70: Cipla Limited: key financial ratios
Table 71: Lupin Limited: key facts
Table 72: Lupin Limited: key financials ($)
Table 73: Lupin Limited: key financials (Rs.)
Table 74: Lupin Limited: key financial ratios
Table 75: Sun Pharmaceutical Industries Ltd.: key facts
Table 76: Sun Pharmaceutical Industries Ltd.: key financials ($)
Table 77: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
Table 78: Sun Pharmaceutical Industries Ltd.: key financial ratios
Table 79: Abbott Laboratories: key facts
Table 80: Abbott Laboratories: key financials ($)
Table 81: Abbott Laboratories: key financial ratios
Table 82: Krka, d. d., Novo mesto: key facts
Table 83: Krka, d. d., Novo mesto: key financials ($)
Table 84: Krka, d. d., Novo mesto: key financials (€)
Table 85: Krka, d. d., Novo mesto: key financial ratios
Table 86: Teva Pharmaceutical Industries Limited: key facts
Table 87: Teva Pharmaceutical Industries Limited: key financials ($)
Table 88: Teva Pharmaceutical Industries Limited: key financial ratios
List of Figures
Figure 1: BRIC generics industry, revenue($bn), 2012-21
Figure 2: BRIC generics industry, revenue($bn), 2012-16
Figure 3: BRIC generics industry, revenue($bn), 2016-21
Figure 4: Brazil generics market value: $ billion, 2012–16
Figure 5: Brazil generics market volume: % of total pharma volume, 2012–16
Figure 6: Brazil generics market geography segmentation: % share, by value, 2016
Figure 7: Brazil generics market value forecast: $ billion, 2016–21
Figure 8: Brazil generics market volume forecast: % of total pharma volume, 2016–21
Figure 9: Forces driving competition in the generics market in Brazil, 2016
Figure 10: Drivers of buyer power in the generics market in Brazil, 2016
Figure 11: Drivers of supplier power in the generics market in Brazil, 2016
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016
Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2016
Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2016
Figure 15: China generics market value: $ billion, 2012–16
Figure 16: China generics market volume: % of total pharma volume, 2012–16
Figure 17: China generics market geography segmentation: % share, by value, 2016
Figure 18: China generics market value forecast: $ billion, 2016–21
Figure 19: China generics market volume forecast: % of total pharma volume, 2016–21
Figure 20: Forces driving competition in the generics market in China, 2016
Figure 21: Drivers of buyer power in the generics market in China, 2016
Figure 22: Drivers of supplier power in the generics market in China, 2016
Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 25: Drivers of degree of rivalry in the generics market in China, 2016
Figure 26: India generics market value: $ billion, 2012–16
Figure 27: India generics market volume: % of total pharma volume, 2012–16
Figure 28: India generics market geography segmentation: % share, by value, 2016
Figure 29: India generics market value forecast: $ billion, 2016–21
Figure 30: India generics market volume forecast: % of total pharma volume, 2016–21
Figure 31: Forces driving competition in the generics market in India, 2016
Figure 32: Drivers of buyer power in the generics market in India, 2016
Figure 33: Drivers of supplier power in the generics market in India, 2016
Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2016
Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2016
Figure 36: Drivers of degree of rivalry in the generics market in India, 2016
Figure 37: Russia generics market value: $ billion, 2012–16
Figure 38: Russia generics market volume: % of total pharma volume, 2012–16
Figure 39: Russia generics market geography segmentation: % share, by value, 2016
Figure 40: Russia generics market value forecast: $ billion, 2016–21
Figure 41: Russia generics market volume forecast: % of total pharma volume, 2016–21
Figure 42: Forces driving competition in the generics market in Russia, 2016
Figure 43: Drivers of buyer power in the generics market in Russia, 2016
Figure 44: Drivers of supplier power in the generics market in Russia, 2016
Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016
Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2016
Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2016
Figure 48: Sanofi SA: revenues & profitability
Figure 49: Sanofi SA: assets & liabilities
Figure 50: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 51: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
Figure 52: Mylan Inc.: revenues & profitability
Figure 53: Mylan Inc.: assets & liabilities
Figure 54: Aurobindo Pharma Limited: revenues & profitability
Figure 55: Aurobindo Pharma Limited: assets & liabilities
Figure 56: Cipla Limited: revenues & profitability
Figure 57: Cipla Limited: assets & liabilities
Figure 58: Lupin Limited: revenues & profitability
Figure 59: Lupin Limited: assets & liabilities
Figure 60: Sun Pharmaceutical Industries Ltd.: revenues & profitability
Figure 61: Sun Pharmaceutical Industries Ltd.: assets & liabilities
Figure 62: Abbott Laboratories: revenues & profitability
Figure 63: Abbott Laboratories: assets & liabilities
Figure 64: Krka, d. d., Novo mesto: revenues & profitability
Figure 65: Krka, d. d., Novo mesto: assets & liabilities
Figure 66: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 67: Teva Pharmaceutical Industries Limited: assets & liabilities
